Lupin's Subsidiary, MedQuimica Acquires Rights to Nine Brands From Bausch Health
“The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness,” said Alexandre Franca, Managing Director, MedQuímica
Lupin Limited announced that its wholly owned subsidiary in Brazil, MedQuímica Indústria Farmacêutica (MedQuímica), has signed a definitive agreement to acquire all rights to nine medicines from BL Indústria Ótica, a subsidiary of Bausch Health Companies.
As part of the transaction, MedQuímica will acquire rights to nine products including Limbitrol, Melleril and Dalmadorm for Central Nervous System related conditions, Bacrocin, Glyquin, Solaquin, Oxipelle and Efurix as topical oncological treatments, and Cuprimine for the treatment of Wilson’s disease.
"The acquired brands are well established and recognised among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness," said Alexandre Franca, Managing Director, MedQumica.
"This transaction enhances our product portfolio in Brazil and strengthens our position in the prescription market," Alexandre added.